Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 3, 2026, 8:43 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 315 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Renal Transplant Failure Clear all
Terminated Phase 2 Interventional Results available

Desensitization of Highly Sensitized Deceased Donor Renal Transplantation Candidates

NCT00986947
View directory record Official record
Conditions
Kidney Failure
Interventions
IVIg and rituximab
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 1, 2017 · Synced Oct 3, 2026, 8:43 PM EDT
Completed Not applicable Interventional

Transplant Navigator Dissemination

NCT01981603
View directory record Official record
Conditions
Kidney Transplant, Renal Failure Chronic Requiring Hemodialysis
Interventions
navigator
Other
Lead sponsor
Catherine Sullivan
Other
Eligibility
18 Years to 70 Years
Enrollment
1,926 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
5
States / cities
Fort Wayne, Indiana • Lexington, Kentucky • Louisville, Kentucky + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2018 · Synced Oct 3, 2026, 8:43 PM EDT
Recruiting No phase listed Observational

Dd-cfDNA and Treg in Prediction of Kidney Transplant Acute Rejection

NCT05084768
View directory record Official record
Conditions
Acute Rejection of Renal Transplant, Graft Failure
Interventions
Donor-derived cell-free DNA
Diagnostic Test
Lead sponsor
Loma Linda University
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 3, 2026, 8:43 PM EDT
Active, not recruiting Phase 4 Interventional

Angiotensin 2 for AKI After OLT

NCT04592744
View directory record Official record
Conditions
Cirrhosis, Liver, End Stage Liver DIsease, Acute Kidney Injury, Liver Transplant; Complications
Interventions
Angiotensin II, Norepinephrine
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Oct 3, 2026, 8:43 PM EDT
Completed Phase 2 Interventional Results available

Combined Kidney and Bone Marrow Transplantation to Prevent Kidney Transplant Rejection

NCT00801632
View directory record Official record
Conditions
Kidney Transplantation, Kidney Failure, Chronic
Interventions
Kidney Transplantation, Bone marrow transplantation, MEDI-507, cyclophosphamide, rituximab, Tacrolimus, corticosteroids, thymic irradiation
Procedure · Biological · Drug + 1 more
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 10, 2015 · Synced Oct 3, 2026, 8:43 PM EDT
Completed Not applicable Interventional

Bone Marrow and Kidney Transplant for Patients With Chronic Kidney Disease and Blood Disorders

NCT01758042
View directory record Official record
Conditions
Chronic Kidney Disease, Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Chronic Myelogenous Leukemia (CML), Chronic Lymphocytic Leukemia (CLL), Non-Hodgkin's Lymphoma (NHL), Hodgkin Disease, Multiple Myeloma, Myelodysplastic Syndrome (MDS), Aplastic Anemia, AL Amyloidosis, Diamond Blackfan Anemia, Myelofibrosis, Myeloproliferative Disease, Sickle Cell Anemia, Autoimmune Diseases, Thalassemia
Interventions
Haploidentical Bone Marrow/Kidney
Procedure
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 70 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 6, 2026 · Synced Oct 3, 2026, 8:43 PM EDT
Completed Phase 2 Interventional

Prevention Of Nephrotoxicity Following Bone Marrow Transplantation Using Urodilatin and Mannitol

NCT00390624
View directory record Official record
Conditions
Renal Dysfunction, Acute Renal Failure, Mortality
Interventions
URODILATIN (ULARITIDE, ATRIAL NATRIURETIC PEPTIDE), MANNITOL
Drug
Lead sponsor
Rocky Mountain Cancer Centers
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 3, 2008 · Synced Oct 3, 2026, 8:43 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Combination Immunosuppressive Therapy to Prevent Kidney Transplant Rejection in Adults

NCT00078559
View directory record Official record
Conditions
Kidney Transplantation, Kidney Disease
Interventions
Alemtuzumab, Sirolimus, Tacrolimus, Kidney transplant, Methylprednisolone (or equivalent), Acetaminophen, Diphenhydramine, Trimethoprim (TMP)/Sulfa (Bactrim, Septra), Valgancyclovir, Acyclovir, Pentamidine, Clotrimazole, Nystatin
Drug · Procedure
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 29, 2018 · Synced Oct 3, 2026, 8:43 PM EDT
Completed Phase 2 Interventional Results available

Pharmacokinetics of LCP-Tacro in Stable Kidney Transplant Patients

NCT00496483
View directory record Official record
Conditions
Renal Failure
Interventions
LCP Tacro (tacrolimus), Prograf
Drug
Lead sponsor
Veloxis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
2
States / cities
Cincinnati, Ohio • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 23, 2015 · Synced Oct 3, 2026, 8:43 PM EDT
Withdrawn No phase listed Observational

Study Correlation Between Blood, Tissue Gene Expression, Donor Derived Cell Free DNA and Histopathology in Kidney Transplant Recipients

NCT05811468
View directory record Official record
Conditions
Transplant;Failure,Kidney, Kidney Transplant, Kidney Rejection Transplant
Interventions
Not listed
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years to 100 Years
Timeline
2023 – 2025
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 19, 2024 · Synced Oct 3, 2026, 8:43 PM EDT
Completed Phase 2 Interventional Results available

Sirolimus and Thymoglobulin to Prevent Kidney Transplant Rejection

NCT00006178
View directory record Official record
Conditions
Kidney Failure
Interventions
Sirolimus, Thymoglobulin
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
Not listed
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 17, 2019 · Synced Oct 3, 2026, 8:43 PM EDT
Terminated Phase 2 Interventional Results available

Antithymocyte Globulin, Clofarabine, and Rituximab in Treating Patients After an Unsuccessful Stem Cell Transplant

NCT00617929
View directory record Official record
Conditions
Cancer
Interventions
anti-thymocyte globulin, rituximab, clofarabine, stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Not listed
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 28, 2017 · Synced Oct 3, 2026, 8:43 PM EDT
Recruiting Not applicable Interventional

A Study to Evaluate the Safety and Effectiveness of the InnAVasc Arteriovenous Graft for Hemodialysis Access in Patients With End-Stage Renal Disease

NCT04671771
View directory record Official record
Conditions
End Stage Renal Disease (ESRD), Kidney Failure, Chronic Renal Disease, Hemodialysis
Interventions
InnAVasc Arteriovenous Graft (IG) surgical implant
Device
Lead sponsor
W.L.Gore & Associates
Industry
Eligibility
18 Years to 90 Years
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
21
States / cities
Phoenix, Arizona • Sarasota, Florida • Tampa, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2025 · Synced Oct 3, 2026, 8:43 PM EDT
Completed Phase 2 Interventional Results available

A Study in Participants With End-Stage Renal Disease

NCT01200290
View directory record Official record
Conditions
Kidney Failure, Chronic
Interventions
LY2127399
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated May 14, 2018 · Synced Oct 3, 2026, 8:43 PM EDT
Recruiting Phase 1Phase 2 Interventional

Safety, Pharmacokinetics, and Efficacy of AT 1501 in Patients Undergoing Kidney Transplant

NCT05027906
View directory record Official record
Conditions
Prevention of Rejection in Kidney Transplant
Interventions
AT-1501
Drug
Lead sponsor
Eledon Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 29, 2025 · Synced Oct 3, 2026, 8:43 PM EDT
Completed Not applicable Interventional Results available

Clinical Evaluation of a Vascular Venous Anastomotic Connector [InterGraft VIG-only Study]

NCT02532621
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Venous InterGraft Connector, sutured arterial anastomosis of an implanted vascular graft for hemodialysis, hemodialysis
Device · Procedure
Lead sponsor
Phraxis, Inc.
Industry
Eligibility
18 Years and older
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
10
States / cities
Dothan, Alabama • Cartersville, Georgia • Macon, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2025 · Synced Oct 3, 2026, 8:43 PM EDT
Terminated Not applicable Interventional Results available

Safety and Efficacy of Angiotech Vascular Wrap Paclitaxel-Eluting Mesh for Hemodialysis Vascular Access

NCT00448708
View directory record Official record
Conditions
Kidney Diseases, ESRD
Interventions
Vascular Wrap Paclitaxel-Eluting Mesh, Lifespan® ePTFE Vascular Graft
Device
Lead sponsor
Angiotech Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
33
States / cities
Birmingham, Alabama • Fresno, California • Inglewood, California + 27 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2011 · Synced Oct 3, 2026, 8:43 PM EDT
Completed No phase listed Observational

Desensitization Protocol for Deceased Donor List

NCT01642225
View directory record Official record
Conditions
Transplant; Failure, Kidney
Interventions
Not listed
Lead sponsor
University of Miami
Other
Eligibility
7 Years to 75 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 20, 2014 · Synced Oct 3, 2026, 8:43 PM EDT
Terminated Not applicable Interventional

A Pilot Study To Evaluate The CreatiVasc Hemoaccess Valve System In Patients Requiring Arteriovenous Graft Placement

NCT01644526
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Hemoaccess Valve System
Device
Lead sponsor
Diaxamed LLC
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Greenville, South Carolina
Source: ClinicalTrials.gov public record
Updated Feb 5, 2018 · Synced Oct 3, 2026, 8:43 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Clazakizumab in Highly-HLA Sensitized Patients Awaiting Renal Transplant

NCT03380962
View directory record Official record
Conditions
Kidney Failure, Chronic, End-Stage Renal Disease, Transplant Glomerulopathy, Transplant;Failure,Kidney, Kidney Transplant Failure and Rejection, Antibody-mediated Rejection, Kidney Transplant; Complications
Interventions
Clazakizumab
Drug
Lead sponsor
Stanley Jordan, MD
Other
Eligibility
15 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 24, 2025 · Synced Oct 3, 2026, 8:43 PM EDT
Completed Not applicable Interventional Results available

Reducing Disparities in Living Donor Transplant Among African Americans

NCT03819686
View directory record Official record
Conditions
Kidney Transplant
Interventions
Living ACTS website, Standard transplant education procedures
Behavioral
Lead sponsor
Emory University
Other
Eligibility
18 Years to 70 Years
Enrollment
416 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 24, 2025 · Synced Oct 3, 2026, 8:43 PM EDT
Recruiting Phase 1Phase 2 Interventional

Study to Evaluate the Safety and Efficacy of the GGTA1 KO Thymokidney in Patients With ESRD

NCT07224763
View directory record Official record
Conditions
ESRD (End-Stage Renal Disease), Kidney Transplantation, Xenotransplantation
Interventions
GGTA1 KO Thymokidney
Biological
Lead sponsor
United Therapeutics
Industry
Eligibility
40 Years to 70 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2076
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 3, 2026, 8:43 PM EDT
Completed Phase 1Phase 2 Interventional

Transplant and Addiction Project (TAP) - 1

NCT00249652
View directory record Official record
Conditions
End Stage Liver Disease, End Stage Renal Disease, Substance-Related Disorders
Interventions
TAP, TAU
Behavioral · Other
Lead sponsor
St. Luke's-Roosevelt Hospital Center
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
3
States / cities
New York, New York • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 14, 2015 · Synced Oct 3, 2026, 8:43 PM EDT
Completed Phase 4 Interventional Results available

Effect of Ferrlecit® Versus Oral Iron on Iron Deficient Chronic Kidney Disease (CKD) Patients

NCT00224055
View directory record Official record
Conditions
Anemia, Iron-Deficiency, Kidney Failure, Chronic
Interventions
Sodium Ferric Gluconate Complex in Sucrose Injection, Ferrous sulfate tablets
Drug
Lead sponsor
Watson Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
23
States / cities
Tucson, Arizona • Los Angeles, California • Palo Alto, California + 20 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2012 · Synced Oct 3, 2026, 8:43 PM EDT